Shanghai Henlius Biotech's (HKG:2696) serplulimab injection in combination with carboplatin and etoposide has been approved by the European Commission for the first-line treatment of adult patients with extensive-stage small cell lung cancer, a Wednesday bourse filing said.
The injection is an anti-PD-1 monoclonal antibody used for the treatment of various types of lung cancer. It has been approved in mainland China to be used in combination with chemotherapy.
The injection will be deployed in Europe under the trade name Hetronifly. The approval implies a centralized marketing authorization for the injection for all the EU member states together with Iceland, Liechtenstein, and Norway.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。